DEF 14C: Cemtrex Stockholders Approve Warrant Provisions via Written Consent

Cemtrex, Inc. announces stockholder approval of certain warrant provisions related to a recent public offering, obtained via written consent from a majority stockholder.

Summary

• Cemtrex, Inc. has obtained stockholder approval for the Warrant Stockholder Approval Provisions related to Series A and Series B warrants issued under an underwriting agreement with Aegis Capital Corp.
• The approval was secured via written consent from a majority stockholder, Saagar Govil, holding approximately 87.60% of the voting equity.
• The approved provisions include alternative cashless exercises, adjustments to exercise prices in certain events, and modifications to anti-dilution clauses.
• The company is issuing this information statement to inform stockholders of the action taken, as required by the Securities Exchange Act of 1934.
• The action will become effective on the 20th day after the definitive Information Statement is mailed to stockholders.
• The company estimates the cost of preparing, printing, and mailing this information statement to be approximately $10,000.
• The offering closed on May 3, 2024, with aggregate gross proceeds to the Company of approximately $10,035,000.

Sentiment

Score: 6

Explanation: The document is primarily informational, detailing the approval of warrant provisions. While the offering provides capital, the potential dilution is a concern. The sentiment is neutral to slightly positive.

Positives

• The company successfully obtained stockholder approval for the Warrant Stockholder Approval Provisions, ensuring compliance with Nasdaq listing rules.
• The recent public offering generated gross proceeds of approximately $10,035,000 for the company.
• The company has access to additional capital through the exercise of warrants.

Negatives

• Existing stockholders will experience dilution in their ownership interests due to the potential issuance of shares upon exercise of the warrants.
• The sale of shares upon warrant exercise could materially and adversely affect the market price of the company's common stock.

Risks

• The potential issuance of shares upon exercise of the warrants will cause dilution to existing stockholders.
• The market price of the company's common stock could be adversely affected by the sale of shares upon warrant exercise.
• The company's future financial performance and ability to meet its obligations are subject to various risks and uncertainties.

Future Outlook

Following effectiveness of the Warrant Stockholder Approval, existing stockholders will suffer dilution in their ownership interests in the future as a result of the potential issuance of shares of common stock upon exercise of the Warrants.

Management Comments

• By Order of the Board of Directors /s/ Saagar Govil Chief Executive Officer and Chairman

Industry Context

This announcement is typical for companies that have recently completed a public offering involving warrants, as they often need to obtain stockholder approval for certain warrant provisions to comply with Nasdaq listing rules.

Comparison to Industry Standards

• The structure of the offering, including the use of common units and pre-funded units with warrants, is a relatively common practice among small-cap companies seeking to raise capital.
• The warrant exercise prices ($0.85) and terms (expiration dates, cashless exercise options, anti-dilution provisions) are generally within the range of what is observed in similar offerings.
• The potential dilution of existing stockholders is a standard risk associated with warrant offerings, and the company's disclosure of this risk is consistent with industry best practices.

Stakeholder Impact

• Existing stockholders will experience dilution in their ownership interests.
• The market price of the company's common stock could be affected by the sale of shares upon warrant exercise.
• The company's ability to execute its business plan could be enhanced by the capital raised through the public offering.

Next Steps

• The Warrant Stockholder Approval Provisions will become effective on the 20th day after the definitive Information Statement is mailed to stockholders.
• The company will continue to be subject to the information and reporting requirements of the Securities Exchange Act of 1934.

Key Dates

Keywords

Warrant Stockholder Approval, Cemtrex, Warrants, Stockholder Approval, Public Offering, Dilution, Nasdaq, Series A Warrants, Series B Warrants, Underwriting Agreement